The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant intralesional daromun (L19IL2/L19TNF) in resectable locally advanced melanoma: An update on the primary outcome and sensitivity analyses (EFS) from the PIVOTAL phase 3 trial.
 
Katharina Kaehler
Honoraria - Bristol-Myers Squibb; Immunocore; MSD; Novartis; Philogen; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Philogen; Pierre Fabre
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche
 
Mirjana Ziemer
Stock and Other Ownership Interests - Sanofi
Honoraria - AstraZeneca; Bristol-Myers Squibb; Delcath Systems; Johnson & Johnson; Kyowa Kirin; Merck Sharp & Dohme; Pfizer; Pierre Fabre; Regeneron; Sun Pharma; Takeda
Travel, Accommodations, Expenses - Kyowa Kirin; Philogen; Pierre Fabre; Recordati; Sun Pharma
 
Jessica Hassel
Honoraria - Bristol Myers Squibb Foundation; Delcath Systems; Immunocore; MSD; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Consulting or Advisory Role - BMS GmbH & Co. KG (Inst); Immunocore (Inst); MSD (Inst); Novartis (Inst); Philogen (Inst); Pierre Fabre (Inst); Sanofi Aventis GmbH (Inst); Sun Pharma
Research Funding - Agenus (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genmab (Inst); Immatics (Inst); Immunocore (Inst); IO Biotech (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Sanofi (Inst); Sanofi Aventis GmbH (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Iovance Biotherapeutics; Sun Pharma
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Genesis Pharma; Medison; Merck; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Philogen; Pierre Fabre
Speakers' Bureau - Genesis Pharma; Medison; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Friedegund Meier
Honoraria - Bristol-Myers Squibb; Immunocore; MSD; Novartis; Philogen; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; MSD; Novartis; Philogen; Pierre Fabre; Sanofi
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Immunocore; MSD; Novartis; Pierre Fabre; Sanofi
 
Lukas Flatz
Consulting or Advisory Role - Philogen; Sanofi
Research Funding - Hookipa Pharma; Philogen
Patents, Royalties, Other Intellectual Property - Hookipa Pharma
 
Caroline Gaudy-Marqueste
Honoraria - BMS france; Pierre Fabre; UCB
Consulting or Advisory Role - Bristol Meyer Squib; Iovance Biotherapeutics; MSD Oncology; Pierre Fabre; Regeneron; Sun Pharma
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cytovation (Inst); Daiichi Sankyo Europe GmbH (Inst); Day One Biopharmaceuticals (Inst); DOT therapeutics (Inst); Dragonfly Therapeutics (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Immunocore (Inst); Incyte (Inst); InflaRx (Inst); IO Biotech (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Kinnate Biopharma (Inst); Merck (Inst); Microbiotica (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Sairopa (Inst); Sotio (Inst)
Travel, Accommodations, Expenses - BMS France; Janssen; MSD Oncology; Pierre Fabre; Regeneron; Sun Pharma; UCB
 
Mario Santinami
No Relationships to Disclose
 
Francesco Russano
No Relationships to Disclose
 
Imke von Wasielewski
Consulting or Advisory Role - MSD; Sanofi/Regeneron
Travel, Accommodations, Expenses - Kyowa Kirin International; Pierre Fabre
 
Thomas Eigentler
Stock and Other Ownership Interests - CureVac
Consulting or Advisory Role - Anaveon; Bristol-Myers Squibb; CureVac; Novartis; Pierre Fabre; Sanofi
Research Funding - CureVac (Inst); Genentech (Inst)
 
Michele Maio
Stock and Other Ownership Interests - Epigen Therapeutics; Theravance
Honoraria - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; MSD; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Alfasigma; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
Patents, Royalties, Other Intellectual Property - DNA Hypomethylating agents for cancer therapy
Travel, Accommodations, Expenses - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
 
Iris Zalaudek
Honoraria - Fotofinder; MSD Oncology; Novartis; Philogen; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - Philogen; Sun Pharma
Travel, Accommodations, Expenses - Sun Pharma
 
Sebastian Haferkamp
Honoraria - Amgen; Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sun Pharma
 
Pietro Quaglino
Consulting or Advisory Role - Bristol Myers Squibb Foundation; MSD Oncology; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Bristol Myers Squibb Foundation; MSD Oncology; Novartis; Pierre Fabre; Roche
 
Julia Welzel
Honoraria - Abbvie; Almirall; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Leo Pharma; Lilly; Mibe; Novartis; Pfizer; Sana Biotechnology; Sanofi
Consulting or Advisory Role - Abbvie; Almirall; Janssen; Novartis; Sanofi
Research Funding - Almirall (Inst)
Travel, Accommodations, Expenses - Abbvie; Almirall; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Leo Pharma; Lilly; Mibe; Novartis; Pfizer; Sana Biotechnology; Sanofi
 
Paolo Ascierto
Consulting or Advisory Role - Anaveon; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Erasca, Inc; Genmab; ImCheck therapeutics; Immunocore; Incyte; Italfarmaco; Medicenna; Menarini Silicon Biosystems; Merck Sharp & Dohme; Moderna Therapeutics; Nouscom; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sun Pharma; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Medicenna (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Philogen; Pierre Fabre
 
Caroline Robert
Honoraria - Bristol-Myers Squibb; immatics; Iovance Biotherapeutics; MaaT Pharma; Merck; Moderna Therapeutics; MSD; Pfizer; Pierre Fabre; Regeneron; Roche; Sun Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; immatics; IO Biotech; Iovance Biotherapeutics; MaaT Pharma; Merck; Moderna Therapeutics; MSD; Pfizer; Pierre Fabre; Regeneron; Roche; Sun Pharma
Travel, Accommodations, Expenses - Pierre Fabre
 
Dirk Schadendorf
Honoraria - Agenus; AstraZeneca; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Japan; immatics; Immunocore; InflarxGmbH; IO Biotech; Iovance Biotherapeutics; Ipsen; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Skyline Diagnostics; Sun Pharma
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; immatics; Immunocore; IO Biotech; Iovance Biotherapeutics; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Philogen; Pierre Fabre; Replimune; Skyline Diagnostics; Sun Pharma
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Pierre Fabre; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Axel Hauschild
Honoraria - Agenus; Almirall Hermal GmbH; Bristol-Myers Squibb; CureVac; Immunocore; Incyte; IO Biotech; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Philogen; Pierre Fabre; Regeneron; Replimune; Roche; Sanofi/Aventis; Skyline Diagnostics; Sun Pharma; Xenthera
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Immunocore; IO Biotech; Merck Serono; Merck Sharp & Dohme; Novartis; Philogen; Regeneron; Replimune; Roche; Sanofi/Aventis
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis